Neuroaxonal Dystrophy, InfantileNCT04027816
A Natural History Study of Infantile Neuroaxonal Dystrophy
An observational study of Neuroaxonal Dystrophy, Infantile, run by Biojiva LLC at 5 sites in 5 countries.
Trial summary
This study is a longitudinal and prospective study of the natural history of infantile neuroaxonal dystrophy (INAD). Read more about this study
- Who is it for?
- Ages 18 months to 10 years
- Conditions the study is for
- Neuroaxonal Dystrophy, Infantile
- How many people
- 43 participants
- Where
- 5 sitesin 5 countries
- Study dates
- 17 Jun 2019to 28 Feb 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 months to 10 years
- All sexes
- No healthy volunteers
- Child
Study population: Living males or females with a diagnosis of classic INAD between 18 months to 10 years of age.
Who may be able to join
- Male or female 18 months to 10 years of age
- Medical history consistent with the symptoms of classic INAD (onset of symptoms between the ages of 6 months and 3 years)
- Homozygous or compound heterozygous PLA2G6 variants
- Signed informed consent form (ICF) prior to entry into the registry
Who cannot join
- Diagnosis of atypical NAD (ANAD)
- Additional underlying diagnosis with features that overlap with INAD
- Unwilling or unable to allow medical record review
- Unwilling or unable to participate in serial assessments every 6 months (including deceased patients)
Trial locations and contacts
5 sites in 5 countries.
5 sites in 5 countries
Saudi Arabia1 site
King Faisal Specialist Hospital and Research Center
Riyadh
About this study
Official title: Protocol RT001-009: A Natural History Study of Infantile Neuroaxonal Dystrophy
This study is a longitudinal and prospective study of the natural history of infantile neuroaxonal dystrophy (INAD).
Read the detailed description
After obtaining informed consent, the study participants' relevant medical records will be collected and reviewed for this study. Next, a clinic visit will be scheduled with the patient's family and an observing MD/DO/MBBS from a sponsor site to confirm and clarify information in the medical records.
A baseline evaluation of clinical status will also be performed during this visit to serve as visit one in this longitudinal, prospective natural history study. Subsequent visits will take place every 6 months, for up to 24 months. Key components of this prospective study at each visit include a neurodevelopment exam tailored for INAD, application of the CHOP-INTEND neurodevelopment scale, the Hammersmith infant neurological examination and the modified Ashworth spasticity scale as well as collection of monthly parental severity scoring and monthly home videos of activities of daily living (ADLs).
Data from this study will be pooled and presented in aggregate, without identification of individual subjects.
- Conditions
- Neuroaxonal Dystrophy, Infantile
- Keywords
- PLA2G6-related NBIA, INAD, PLA2G6
- Medical subject headings
- Neuroaxonal Dystrophies
What is being measured
The primary outcome is the main question the study is designed to answer.
INAD Mortality
Overall analysis
Measured: 1-2 years of follow-up is planned
Secondary outcomes (4)
INAD Morbidity
Videotaped, structured neurological assessment
Measured: 1-2 years of follow-up is planned
INAD Morbidity
CHOP-INTEND Neuro-development Score
Measured: 1-2 years of follow-up is planned
INAD Morbidity
Hammersmith infant neurological examination
Measured: 1-2 years of follow-up is planned
INAD morbidity
Modified Ashworth spasticity scale
Measured: 1-2 years of follow-up is planned
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2019
- Study start17 Jun 2019
- Primary completion14 Feb 2022
- Study completion28 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuroaxonal Dystrophy, InfantileStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biojiva LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Peter Milner, MD, Study director, Biojiva LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04027816
- Sponsor's protocol ID
- RT001-009
- Status last verified
- Apr 2022
- First submitted
- 16 Jul 2019
- Last updated
- 8 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Protocol RT001-009: A Natural History Study of Infantile Neuroaxonal Dystrophy
- ClinicalTrials.gov ID
- NCT04027816
- Acronym / sponsor ID
- RT001-009
- Conditions
- Neuroaxonal Dystrophy, Infantile
- Keywords
- PLA2G6-related NBIA, INAD, PLA2G6
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- Biojiva LLCIndustry (pharma, biotech, devices)
- Study start
- 17 Jun 2019 (actual)
- Primary completion
- 14 Feb 2022 (actual)
- Study completion
- 28 Feb 2022 (actual)
- First posted
- 22 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a longitudinal and prospective study of the natural history of infantile neuroaxonal dystrophy (INAD).
Detailed description
After obtaining informed consent, the study participants' relevant medical records will be collected and reviewed for this study. Next, a clinic visit will be scheduled with the patient's family and an observing MD/DO/MBBS from a sponsor site to confirm and clarify information in the medical records.
A baseline evaluation of clinical status will also be performed during this visit to serve as visit one in this longitudinal, prospective natural history study. Subsequent visits will take place every 6 months, for up to 24 months. Key components of this prospective study at each visit include a neurodevelopment exam tailored for INAD, application of the CHOP-INTEND neurodevelopment scale, the Hammersmith infant neurological examination and the modified Ashworth spasticity scale as well as collection of monthly parental severity scoring and monthly home videos of activities of daily living (ADLs).
Data from this study will be pooled and presented in aggregate, without identification of individual subjects.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 months to 10 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Living males or females with a diagnosis of classic INAD between 18 months to 10 years of age.
Key inclusion criteria (4 listed)
- Male or female 18 months to 10 years of age
- Medical history consistent with the symptoms of classic INAD (onset of symptoms between the ages of 6 months and 3 years)
- Homozygous or compound heterozygous PLA2G6 variants
- Signed informed consent form (ICF) prior to entry into the registry
Key exclusion criteria (4 listed)
- Diagnosis of atypical NAD (ANAD)
- Additional underlying diagnosis with features that overlap with INAD
- Unwilling or unable to allow medical record review
- Unwilling or unable to participate in serial assessments every 6 months (including deceased patients)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
INAD Mortality
Time frame: 1-2 years of follow-up is planned
Overall analysis
4 secondary outcomes
INAD Morbidity
Time frame: 1-2 years of follow-up is planned
INAD Morbidity
Time frame: 1-2 years of follow-up is planned
INAD Morbidity
Time frame: 1-2 years of follow-up is planned
INAD morbidity
Time frame: 1-2 years of follow-up is planned
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2022.
- Individual participant dataSharing planned: No
Related trials for Neuroaxonal Dystrophy, Infantile
RecruitingObservational study
TIRCON International NBIA Registry
Neurodegeneration With Brain Iron Accumulation (NBIA), Pantothenate Kinase-associated Neurodegeneration (PKAN)
Active, not recruitingPhase 2/3
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
Infantile Neuroaxonal Dystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Milner, MD study director
Biojiva LLC
5 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuroaxonal Dystrophy, Infantile, run by Biojiva LLC at 5 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in China, Egypt, India, Saudi Arabia, Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
INAD Mortality (time frame: 1-2 years of follow-up is planned). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2022.